|
03 Apr 2019 |
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
|
|
03 Apr 2019 |
Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody
|
|
03 Apr 2019 |
Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting
|
|
03 Apr 2019 |
Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects
|
|
03 Apr 2019 |
Pieris Pharmaceuticals Presents Preclinical Data for GPC3/4-1BB Bispecific PRS-342 at the 2019 American Association for Cancer Research
|
|
02 Apr 2019 |
Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019
|
|
02 Apr 2019 |
Apexigen Presents Clinical Data On CD40 Antibody APX005M In Metastatic Melanoma At The AACR Annual Meeting 2019
|
|
02 Apr 2019 |
Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11
|
|
02 Apr 2019 |
Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019
|
|
02 Apr 2019 |
Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting
|
|
02 Apr 2019 |
Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010
|
|
02 Apr 2019 |
Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma
|
|
02 Apr 2019 |
Humanigen Announces Preliminary Results From Ifabotuzumab Phase I Study Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
|
|
02 Apr 2019 |
Celldex Presents Promising Data from CDX-527 Bispecific and TAM Receptor Programs at American Association for Cancer Research (AACR) Annual Meeting 2019
|
|
02 Apr 2019 |
FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin
|
|
01 Apr 2019 |
Apexigen Announces New Clinical Data on APX005M in Combination Therapy for Pancreatic Cancer at the AACR Annual Meeting 2019
|
|
01 Apr 2019 |
Bolt Biotherapeutics Presents Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference
|
|
01 Apr 2019 |
Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy
|
|
01 Apr 2019 |
European Medicines Agency Accepts Takeda’s Marketing Authorization Application for a Subcutaneous Formulation of Vedolizumab for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis and Crohn’s Disease
|
|
01 Apr 2019 |
Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults
|
|
30 Mar 2019 |
CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis
|
|
30 Mar 2019 |
Northern Biologics Reports Initial Phase I Data for MSC-1 at AACR
|
|
30 Mar 2019 |
Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing
|
|
28 Mar 2019 |
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
|
|
27 Mar 2019 |
Tizona Announces Initiation of Phase 1/1b Study with Novel Cancer Immunotherapy TTX-030 and First Public Presentation of Pre-Clinical Data with TTX-030 at AACR 2019
|
